Health emergencies: let’s get prepared without leaving cancer patients behind
ESMO is advocating for secondary and tertiary care levels to be included into international agreements and WHO’s documents to respond to pandemics
Access to high-quality care for sarcomas is still unequal worldwide
Delays and poor patient journey are reported in resource-constrained countries, while awareness campaigns and healthcare service reorganisation have improved rare cancer management in more developed areas
COVID-19 vaccination is key to restoring early-phase anticancer drug development
Vaccination among cancer patients should not affect their participation in clinical trials and levels of acceptance of the vaccine are high
Optimising clinical trials for greater inclusiveness
Oncologists are aiming to capitalise on lessons learned from the COVID-19 pandemic and design more inclusive clinical trials, optimise trial endpoints and make better use of real-world evidence.
Innovation is creating new ways to support oncologists
How ESMO is transforming the challenges from the COVID-19 pandemic into opportunities to re-shape the future of the oncology community
Should we invest more in registry data?
During the COVID-19 pandemic, real-world data have shown they can support clinical decision-making in complex situations but extensive bureaucracy is still a limiting factor
Vaccinate cancer patients against COVID-19: experts address major uncertainties
At an ESMO Live Roundtable, a panel of experts discussed the benefits and risk of COVID-19 vaccination in patients with cancer, the practicalities of vaccinating those undergoing immunosuppressant treatment and the potential advantages and disadvantages of flexible dosing intervals.
